Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy
27 June 2023, Lion TCR, a clinical-stage T-cell immunotherapy company, is thrilled to announce the successful completion of its USD 40 million Series B2 financing round. Guangzhou Industrial Investment and Capital Operation Holding Group Ltd. led the financing with participation from Guangzhou Guoju Investment and CSPC NARD Capital Fund. The funds raised will be used primarily to support Lion TCR's clinical trials on hepatitis B virus (HBV)-specific TCR T cell therapy, while also facilitating th
Source: yahoo.com
